Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

AZGP1 Protein Expression in Hormone-Naive Advanced Prostate Cancer Treated with Primary Androgen Deprivation Therapy

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Multicentric Atrial Strain COmparison between Two Different Modalities: MASCOT HIT Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Limited diagnostic utility of Chromogranin A measurements in workup of neuroendocrine tumors

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Atherosclerosis Imaging with 18F-Sodium Fluoride PET

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  1. Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Novel functions of the luteinizing hormone/chorionic gonadotropin receptor in prostate cancer cells and patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Postembolization Syndrome after Prostatic Artery Embolization: A Systematic Review

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

Vis graf over relationer

Biomarkers for predicting the risk of castration-resistant prostate cancer (CRPC) in men treated with primary androgen deprivation therapy (ADT) are lacking. We investigated whether Zinc-alpha 2 glycoprotein (AZGP1) expression in the diagnostic biopsies of men with hormone-naïve prostate cancer (PCa) undergoing primary ADT was predictive of the development of CRPC and PCa-specific mortality. The study included 191 patients who commenced ADT from 2000 to 2011. The AZGP1 expression was evaluated using immunohistochemistry and scored as high or low expression. The risks of CRPC and PCa-specific mortality were analyzed using stratified cumulative incidences and a cause-specific COX regression analysis for competing risk assessment. The median follow-up time was 9.8 (IQR: 6.1-12.7) years. In total, 94 and 97 patients presented with low and high AZGP1 expression, respectively. A low AZGP1 expression was found to be associated with a shorter time to CRPC when compared to patients with a high AZGP1 expression (HR: 1.5; 95% CI: 1.0-2.1; p = 0.03). However, the multivariable analysis demonstrated no added benefit by adding the AZGP1 expression to prediction models for CRPC. No differences for PCa-specific mortality between the AZGP1 groups were observed. In conclusion, a low AZGP1 expression was associated with a shorter time to CRPC for PCa patients treated with first-line ADT but did not add any predictive information besides well-established clinicopathological variables.

OriginalsprogEngelsk
Artikelnummer520
TidsskriftDiagnostics
Vol/bind10
Udgave nummer8
ISSN2075-4418
DOI
StatusUdgivet - aug. 2020

ID: 60879479